Encephalitis Treatment Market - By Disease Type (Primary, Secondary), By Treatment (Antiviral, Steroid, Antibiotic, Immunoglobulin, Plasmapheresis), By Route of Administration (Oral, Parenteral), By End-user (Hospital), Global Forecast 2023 - 2032

Encephalitis Treatment Market Size

Encephalitis Treatment Market size was evaluated to be around USD 20.6 billion in 2022 and is anticipated to exhibit sustainable growth at a CAGR of around 4.7% during the forecast period. This is attributed primarily to factors such as the growing incidence of encephalitis, increasing awareness about disease treatments, and healthcare expenditure.
 

Encephalitis is a rare but life-threatening brain disease. Encephalitis is a brain inflammation that occurs due to an infection caused by viruses, bacteria, or immune system malfunction. Encephalitis causes various physical and neurological symptoms such as fever, headaches, stiff neck, muscle weakness and pain, behavioural changes, confusion, memory issues, seizures, sensitivity to light and loss of consciousness. Prompt diagnosis and treatment of encephalitis is crucial as it can affect the individual severely.
 

The symptoms of encephalitis can be mild to severe and needs to be treated urgently. The management of encephalitis is done using antiviral drugs, steroids, antibiotics, immunoglobulin therapies, plasmapheresis, and other medications like anticonvulsant, and antifungal medications.
 

COVID-19 Impact

During COVID-19, the global encephalitis treatment market was obstructed due to the lockdown and travel restrictions imposed by the government all over the globe. Due to this, the number of people opting for encephalitis treatment and the number of hospitalizations decreased, hampering the market. Later, as COVID instances decreased, the market experienced considerable growth as there was an increase in the number of patients opting for the treatments and new product launches.
 

Encephalitis Treatment Market Trends

Encephalitis is a global concern due to its high mortality and morbidity. It is important to treat such diseases in order to overcome the mortality issues all over the globe. According to National Institute of Health, incidences of encephalitis worldwide range from 3.5 to 7.4 per 100,000 patients per year, despite improved treatment options for encephalitis. According to the same studies, among the encephalitis patients, encephalitis leads to death in 5–20% of them. According to the article in the Journal of Infection, in 2019, 1,444,720 incident cases of encephalitis and 89,900 deaths due to encephalitis were estimated.
 

The growing geriatric population are at high risk of getting infection by viruses which cause encephalitis. Due to the increasing prevalence of encephalitis, pharmaceutical and biotechnology companies have increased their investment in R&D in order to develop new treatment options to treat various types of encephalitis. The surging initiatives by government and private organizations for the treatment of encephalitis will drive the market trends.
 

Encephalitis Treatment Market Analysis

Based on disease type, the market is subdivided into primary and secondary encephalitis. The primary encephalitis segment dominated global encephalitis treatment market in 2022. Primary encephalitis refers to brain inflammation caused by a viral or bacterial infection. It is the most common type of encephalitis due to herpes simplex viruses, varicella zoster viruses, and rubella viruses. Viruses are the major cause of primary encephalitis and approximately 70% of the cases are caused due to viruses. Increasing prevalence of encephalitis drives the segment landscape.
 

Based on treatment type, the global encephalitis treatment market is classified into antiviral agents, steroids, antibiotics, immunoglobulin therapy, plasmapheresis, and other treatments. The antiviral agent segment accounted for the largest share in 2022. The antiviral agents are used for treating primary encephalitis, which is caused by various viruses. Factors such as the increasing prevalence of primary encephalitis, growing demand for treatment, cost-effectiveness, easy availability, efficiency, and increased prescription rate are contributing to the growth of this segment.
 

Based on route of administration, the encephalitis treatment market is subdivided into oral, parenteral, and other routes of administration. The oral segment held the highest market share in 2022 owing to high adoption, non-invasiveness, patient compliance, and convenience. Many of the drugs used for encephalitis treatment are administered orally; for instance, Acyclovir, valacyclovir, and famciclovir are available as oral formulations. These factors will enhance the overall market share.
 

Based on end-user, the encephalitis treatment market is subdivided into hospitals, specialty clinics, and other end-users. Among the end-user segments, the hospital segment held the highest revenue share of the market in 2022. The increasing prevalence of encephalitis, development of new therapies for treating encephalitis, growing government initiatives in launching the new drugs, and increased number of admissions for encephalitis in hospitals accelerated the growth of this segment.
 

Based on region, encephalitis treatment market is subdivided into North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa. In 2022, the North America held the highest revenue in this market, owing to an increased prevalence of encephalitis, increasing investments for R&D for developing new drugs for treating encephalitis, presence of key players, and well-developed healthcare infrastructure. During the forecast period, Asia Pacific segment is anticipated to witness significant growth due to the raising prevalence of encephalitis and increased government initiatives and fundings.
 

In North America segment, U.S. accounted for the highest market share in 2022 owing to the better access to treatment options, strong promising pipeline drugs, increasing number of product launches, acquisitions and growing awareness and demand for encephalitis treatment.
 

Encephalitis Treatment Market Share

The key players in encephalitis treatment market are :

• Pfizer Inc
• Merck & Co., Inc
• Allergan
• GlaxoSmithKline plc
• Abbott Laboratories
• FHoffmann-La Roche Ltd
• Sanofi
• Teva Pharmaceutical Industries Ltd
• Basilea Pharmaceutical Ltd
• Melinta Therapeutics LLC

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.
 

Encephalitis Treatment Industry News:

• In August 2021, Pfizer got approval from United States Food and Drug Administration for Tick-Borne Encephalitis (TBE) Vaccine named as TICOVAC.
   
• In December 2019, GlaxoSmithKline plc announced the completion of the divestment of travel vaccines Rabipur (tradename Rabavert in the US) for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic.

The encephalitis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Billion from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Disease Type

• Primary encephalitis
• Secondary encephalitis

By Treatment

• Antiviral agents
• Steroids injections
• Antibiotics
• Immunoglobulin therapy
• Plasmapheresis
• Other treatments

By Route of Administration

• Oral
• Parenteral
• Other routes of administration

By End-user

• Hospitals
• Specialty clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa